Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. has completed a $4.27 million entitlement offer, strongly backed by shareholders and new investors, to advance their Phase 2 ACCENT trial in pancreatic cancer. The trial is progressing well, with 19 out of 26 patients already enrolled, and interim results are expected in the third quarter of 2024. This financial boost aims to support their leading FAK inhibitor’s development and a new trial in ovarian cancer.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
